News & Press Releases

News & Press Releases

Feb 09, 2021
All eight patients treated with OTL-203 show stable cognitive function, motor function and growth within the normal range at multiple data points post-treatment Supportive initial OTL-201 biomarker data for mucopolysaccharidosis type IIIA (MPS-IIIA or Sanfilippo syndrome type A) in three patients
Feb 05, 2021
Strengthened Financial Position Supports Execution into the First Half of 2023 BOSTON and LONDON, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that it has executed a securities purchase agreement to raise gross proceeds of $150
Jan 29, 2021
Commercial Launch of Libmeldy™ in Europe On-Track for 1H 2021 BOSTON and LONDON, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the appointment of Braden Parker to the role of Chief Commercial Officer (CCO). In this capacity, Mr.
Jan 11, 2021
Preparations on Track for First Half 2021 Commercial Launch of Libmeldy™ (OTL-200), the First Approved Product for Metachromatic Leukodystrophy (MLD) in the EU Filing Strategy for OTL-200 Biologics License Application (BLA) in MLD in the U.S. to be Communicated by Mid-2021 Following Additional
The site uses cookies to provide you with a more responsive and personalized service. By using this site, you agree to our use of cookies as set out in our cookie notice.

Please read our privacy notice and cookie notice for more information on the cookies we use and how to delete or block the use of cookies.